WO2010094900A1 - Moyens pour la purification d'une protéine de la coagulation, et procèdes pour sa mise en oeuvre - Google Patents
Moyens pour la purification d'une protéine de la coagulation, et procèdes pour sa mise en oeuvre Download PDFInfo
- Publication number
- WO2010094900A1 WO2010094900A1 PCT/FR2010/050293 FR2010050293W WO2010094900A1 WO 2010094900 A1 WO2010094900 A1 WO 2010094900A1 FR 2010050293 W FR2010050293 W FR 2010050293W WO 2010094900 A1 WO2010094900 A1 WO 2010094900A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- factor
- human
- coagulation
- affinity
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 234
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 230
- 230000015271 coagulation Effects 0.000 title claims abstract description 147
- 238000005345 coagulation Methods 0.000 title claims abstract description 147
- 238000000034 method Methods 0.000 title claims description 88
- 108091023037 Aptamer Proteins 0.000 claims abstract description 160
- 230000027455 binding Effects 0.000 claims abstract description 49
- 239000007787 solid Substances 0.000 claims abstract description 46
- 241000282414 Homo sapiens Species 0.000 claims description 104
- 150000007523 nucleic acids Chemical class 0.000 claims description 67
- 102000039446 nucleic acids Human genes 0.000 claims description 65
- 108020004707 nucleic acids Proteins 0.000 claims description 65
- 230000009261 transgenic effect Effects 0.000 claims description 51
- 235000013336 milk Nutrition 0.000 claims description 41
- 210000004080 milk Anatomy 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 39
- 239000008267 milk Substances 0.000 claims description 39
- 239000000463 material Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 30
- 210000002381 plasma Anatomy 0.000 claims description 28
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 26
- 108010023321 Factor VII Proteins 0.000 claims description 26
- 125000006850 spacer group Chemical group 0.000 claims description 25
- 229940012413 factor vii Drugs 0.000 claims description 23
- 108090000144 Human Proteins Proteins 0.000 claims description 21
- 102000003839 Human Proteins Human genes 0.000 claims description 21
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 17
- 108010076282 Factor IX Proteins 0.000 claims description 17
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 16
- 229960004222 factor ix Drugs 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 15
- 102000053602 DNA Human genes 0.000 claims description 15
- 108010014173 Factor X Proteins 0.000 claims description 7
- 239000012149 elution buffer Substances 0.000 claims description 7
- 108010080865 Factor XII Proteins 0.000 claims description 6
- 102000000429 Factor XII Human genes 0.000 claims description 6
- 108010071289 Factor XIII Proteins 0.000 claims description 6
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 6
- 108010094028 Prothrombin Proteins 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 6
- 102100026966 Thrombomodulin Human genes 0.000 claims description 5
- 108010079274 Thrombomodulin Proteins 0.000 claims description 5
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 4
- 108010014172 Factor V Proteins 0.000 claims description 4
- 108010054218 Factor VIII Proteins 0.000 claims description 4
- 102000001690 Factor VIII Human genes 0.000 claims description 4
- 108090000481 Heparin Cofactor II Proteins 0.000 claims description 4
- 102100030500 Heparin cofactor 2 Human genes 0.000 claims description 4
- 229940096437 Protein S Drugs 0.000 claims description 4
- 108010066124 Protein S Proteins 0.000 claims description 4
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims description 4
- 229960000301 factor viii Drugs 0.000 claims description 4
- 230000003100 immobilizing effect Effects 0.000 claims description 4
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 102100029117 Coagulation factor X Human genes 0.000 claims description 3
- 101800004937 Protein C Proteins 0.000 claims description 3
- 102000017975 Protein C Human genes 0.000 claims description 3
- 102100027378 Prothrombin Human genes 0.000 claims description 3
- 101800001700 Saposin-D Proteins 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 3
- 229940012444 factor xiii Drugs 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 229960000856 protein c Drugs 0.000 claims description 3
- 229940039716 prothrombin Drugs 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims description 2
- 102100035792 Kininogen-1 Human genes 0.000 claims description 2
- 108010000499 Thromboplastin Proteins 0.000 claims description 2
- 102000002262 Thromboplastin Human genes 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 2
- 230000005291 magnetic effect Effects 0.000 claims description 2
- 230000005298 paramagnetic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 102000004506 Blood Proteins Human genes 0.000 claims 3
- 108010017384 Blood Proteins Proteins 0.000 claims 3
- JOJYUFGTMHSFEE-YONYXQDTSA-M Cytarabine ocfosphate Chemical compound [Na+].O[C@H]1[C@H](O)[C@@H](COP([O-])(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 JOJYUFGTMHSFEE-YONYXQDTSA-M 0.000 claims 2
- 102000029301 Protein S Human genes 0.000 claims 2
- 239000000758 substrate Substances 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 199
- 238000000746 purification Methods 0.000 description 56
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 45
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 42
- 239000000499 gel Substances 0.000 description 40
- 238000010828 elution Methods 0.000 description 36
- 125000003729 nucleotide group Chemical group 0.000 description 31
- 239000002773 nucleotide Substances 0.000 description 30
- 241000283973 Oryctolagus cuniculus Species 0.000 description 27
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 25
- 238000002347 injection Methods 0.000 description 25
- 239000007924 injection Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 239000000872 buffer Substances 0.000 description 23
- 239000011780 sodium chloride Substances 0.000 description 23
- 241000124008 Mammalia Species 0.000 description 20
- 239000007858 starting material Substances 0.000 description 20
- 239000003446 ligand Substances 0.000 description 19
- 239000011534 wash buffer Substances 0.000 description 19
- 238000002835 absorbance Methods 0.000 description 16
- 229940099816 human factor vii Drugs 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 108010090804 Streptavidin Proteins 0.000 description 13
- 229960002685 biotin Drugs 0.000 description 13
- 235000020958 biotin Nutrition 0.000 description 13
- 239000011616 biotin Substances 0.000 description 13
- 230000008929 regeneration Effects 0.000 description 13
- 238000011069 regeneration method Methods 0.000 description 13
- 238000001042 affinity chromatography Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 229920002477 rna polymer Polymers 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 229960000027 human factor ix Drugs 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
- 108010054265 Factor VIIa Proteins 0.000 description 10
- 229940012414 factor viia Drugs 0.000 description 10
- 230000000717 retained effect Effects 0.000 description 10
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 10
- 230000003993 interaction Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000005012 migration Effects 0.000 description 8
- 238000013508 migration Methods 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 108010076119 Caseins Proteins 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 102000011632 Caseins Human genes 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000011067 equilibration Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 101710087237 Whey acidic protein Proteins 0.000 description 4
- 208000015294 blood coagulation disease Diseases 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011210 chromatographic step Methods 0.000 description 4
- 239000012501 chromatography medium Substances 0.000 description 4
- 230000009852 coagulant defect Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000006193 liquid solution Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 3
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 102100031013 Transgelin Human genes 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 230000003024 amidolytic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- 229960001134 von willebrand factor Drugs 0.000 description 3
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108091008102 DNA aptamers Proteins 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 101150070547 MAPT gene Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000005411 Van der Waals force Methods 0.000 description 2
- 102100028885 Vitamin K-dependent protein S Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 235000020244 animal milk Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 239000003914 blood derivative Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- 229940021722 caseins Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000057593 human F8 Human genes 0.000 description 2
- 229960000900 human factor viii Drugs 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 108010051423 streptavidin-agarose Proteins 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108010048049 Factor IXa Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 102100023413 GRB2-related adapter protein Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000829735 Homo sapiens GRB2-related adapter protein Proteins 0.000 description 1
- 101000734214 Homo sapiens Unconventional prefoldin RPB5 interactor 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102100038124 Plasminogen Human genes 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101150059663 WAP gene Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000603 anti-haemophilic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical group OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Definitions
- the present invention relates to the field of the purification of coagulation proteins, which can be used as active ingredients of medicaments
- Coagulation proteins have long been active ingredients of drugs.
- coagulation proteins used as drug active ingredients mention may be made in particular of factor VII, factor VIII, thrombin or even von Willebrand factor.
- coagulation proteins were exclusively obtained by purification from human plasma.
- certain coagulation proteins have been obtained in the form of recombinant proteins produced in body fluids of transgenic mammals, for example in the milk of transgenic mammals.
- the starting material containing the coagulation protein to be purified consists of a complex constitution material, in which the protein of interest is present in combination with a very large number of substances, including proteins, lipids, carbohydrates, amino acids, mineral salts, cellular debris and metabolic wastes such as urea, uric acid or bilirubin.
- the coagulation protein used as the active ingredient must be present in a highly purified form and not be associated with undesirable substances that may be present. deleterious to the body, including other coagulation proteins, albumin, immunoglobulins, or degradation products of the above-mentioned proteins.
- coagulation proteins include methods for purifying Factor VIII, anti-thrombin-III, plasminogen, Factor VII or von Willebrand factor.
- All the known processes comprise a succession of selective separation steps based on protein precipitation steps, passage on chromatography followed by sequential elution steps, filtration steps in depth, ultrafiltration or even concentration steps.
- the invention provides an affinity support for the selective binding of a coagulation protein, comprising a solid support material on which nucleic aptamers specifically binding to said coagulation protein are immobilized.
- said nucleic aptamers consist of deoxyribonucleic aptamers.
- the invention also relates to a method for immobilizing a coagulation protein on a support, comprising a step during which a sample containing said coagulation protein is brought into contact with an affinity support.
- It also relates to a method for purifying a coagulation protein comprising the following steps: a) contacting a sample containing a coagulation protein with an affinity support as defined above, in order to forming complexes between (i) the nucleic aptamers immobilized on said affinity support and (ii) said coagulation protein, and b) releasing the protein from the complexes formed in step a), and c) recovering said coagulation protein in a purified form.
- It also relates to a purified composition of a recombinant human coagulation protein comprising at least 99.9% by weight of said recombinant human protein and which is substantially free of non-human proteins
- FIG. 1 illustrates a chromatography profile obtained during the implementation of the method for purifying a recombinant human factor VII produced in rabbit milk with the affinity support in which human anti-FVII nucleic aptamers are immobilized.
- the absorbance value O.D.
- Figure 2 shows the curve of the measured values of absorbance at 280 nm versus time.
- Figure 3 is a schematic of an SDS PAGE electrophoresis gel with commassie blue staining for relative band quantization. From the left to the right of the gel in Figure 3 the tracks represent the migration results of the following starting products, from the left to the right of the figure:
- FIG. 4 represents the curve of the measurement values of the absorbance at 280 nm as a function of time.
- FIG. 5 is a schematic of an SDS PAGE electrophoresis gel. From the left to the right of the gel in Figure 5 the tracks represent the migration results of the following starting materials:
- T FIX purified plasma human factor IX control.
- Figure 6 shows the curve of measured values of absorbance at 280 nm versus time.
- peak # 1 is the fraction of the starting material that was not retained on the column.
- Peak No. 2 corresponds to the elution fraction.
- FIG. 7 represents a snapshot of a gel of the starting product as well as the eluted product was analyzed in SDS PAGE with silver nitrate staining in order to visualize the elimination of impurities: lane n ° 1 corresponds to the fraction from the starting material and run No. 2 to the elution fraction. Despite the high purity of the starting material, it is found that the eluted fraction no longer contains contaminant or degraded forms
- Figure 8 shows the binding curves of the Mapt2 immobilized aptamer to recombinant human Factor VII produced in the milk of a transgenic rabbit.
- the arrows correspond to the time of the different injections, respectively from left to right in FIG. 8: 1: injection of the recombinant factor VII; 2: injection of a 1M NaCl buffer; 3: injection of a 2M NaCl buffer, 4: injection of a 3M NaCl buffer; 5: injection of a 50 mM Tris buffer, 10 mM EDTA.
- abscissa the time expressed in seconds; on the ordinate; the value of the response signal, expressed in arbitrary units (RU).
- Figure 9 shows the binding curves of the immobilized aptaptin Mapt2 to recombinant human factor VII produced in the milk of a transgenic rabbit.
- the arrows correspond to the time of the different injections, respectively from left to right in Figure 9: 1: 50% propylene glycol; 2: EDTA at 10 mM.
- a method for purifying coagulation proteins comprising a chromatography step during which a specific binding of the protein of interest takes place on a ligand previously immobilized on the support of chromatography, then release of the protein of interest retained on said support and recovery of the purified protein in the volume of the eluate.
- a method for the purification of coagulation proteins comprising a step of specific binding of the coagulation protein of interest on a support on which are immobilized nucleic aptamers specifically binding to said protein of interest, followed by a step of recovering said purified protein of interest.
- affinity chromatography supports on which are immobilized nucleic aptamers specific for the coagulation protein of interest that is to say including in the form of compounds immobilized compounds comprising such nucleic aptamers can be used successfully in methods for obtaining coagulation proteins, which can be used as active ingredients of a medicament.
- the present invention relates to an affinity support for the selective binding of a coagulation protein, comprising a solid support material on which are immobilized nucleic aptamers specifically binding to said coagulation protein, including in the form of compounds comprising such nucleic aptamers.
- Nucleic aptamer molecules specifically binding to the coagulation protein of interest, as well as compounds comprising such nucleic aptamers, constitute specific binding sites of said target protein carried by said solid support material.
- nucleic aptamers single-stranded nucleic acids having a length of 5 to 120 nucleotides in length and which specifically bind to a coagulation protein.
- compounds comprising a nucleic aptamer, there are also encompassed compounds which comprise in their structure said nucleic acids defined above.
- compounds comprising a deoxyribonucleic acid specifically binding to a human or mammalian coagulation protein include those compounds wherein said nucleic acid is included in a structure comprising a biotin molecule.
- an affinity support as defined above allows efficient immobilization of the coagulation protein of interest, which may also be called "target protein", in the present description.
- An affinity support as defined above has a high adsorption capacity of the target protein, since contacting the solid support with a liquid solution containing the coagulation protein to be purified makes it possible to saturate at least 50% of the target protein. one hundred of the target sites carried by the solid support.
- the molecules of the coagulation protein which are specifically attached to the nucleic aptamer molecules can then be eluted from the affinity support with a good yield of at least 75 percent. .
- the affinity support of the invention has a high specificity for the coagulation protein of interest, since said coagulation protein can be found with a degree of purity of up to 99. 95 percent by weight, based on the total weight of the proteins contained in the eluate.
- an increase of two orders of magnitude of the purity of the coagulation protein of interest can still be obtained with an affinity support according to the invention, using as starting material a composition comprising the target protein coagulation at a high degree of purity, for example more than 98% by weight, relative to the total weight of the proteins contained in said starting material. It is specified that such an increase in purity is obtained even when the impurities present in the starting product have structural or physicochemical characteristics very close to those of the target protein of the coagulation that is to be purified.
- the affinity support of the invention makes it possible to purify very distinct primary sequence coagulation proteins, such as human factor VII and factor IX. It has also been shown that the affinity support of the invention makes it possible to purify coagulation proteins from starting materials of complex composition, such as a plasma composition enriched in human factor IX and a transgenic animal milk for Human factor IX, with high specificity of binding to said coagulation protein of interest. It has also been shown that the affinity support of the invention makes it possible to selectively purify a human coagulation protein from a starting medium also comprising a non-human orthologous protein, for example from a dermal milk. transgenic animal for human factor IX, said milk also comprising Factor IX naturally produced by said transgenic animal, said Factor IX naturally produced by said transgenic animal (or endogenous FIX) which may be for example a porcine FIX.
- the affinity support of the invention makes it possible to selectively purify a human coagulation protein from a starting medium also comprising a non-human orthologous protein, for example from a dermal milk.
- transgenic animal for human factor VII said milk also comprising Factor VII naturally produced by said transgenic animal, said Factor VII naturally produced by said transgenic animal (or endogenous FVII) which may be for example a rabbit FVII
- the immobilization of nucleic aptamers on the solid support material is irreversible and durable, since the presence of nucleic aptamers detached from the support is not detectable in the eluate solution.
- the affinity support of the invention can be "regenerated” by eliminating the proteins that remain attached to the support after elution for a very large number of times without significantly altering (i) its absorption capacity. the target coagulation protein, (ii) its specificity with respect to said target protein, or (iii) its absence of releasing nucleic aptamers immobilized on the solid support material.
- the regeneration of the affinity support of the invention can be carried out according to known techniques and with known regenerating agents, such as urea.
- nucleic acids used as ligands of the coagulation protein of interest have many advantages. Due to their oligonucleotide nature aptamers possess low immunogenicity and high resistance to stringent physicochemical conditions (presence of urea, DMSO, very acidic or very basic pH, use of organic solvents or high temperature) allowing for a variety of safety control strategies, in particular safety against viruses or unconventional pathogens, in the context of use as an affinity ligand. In addition, their selectivity is important. Finally, as already mentioned, the production of aptamers involves relatively limited costs.
- the combination of the above characteristics of the affinity support of the invention materialize the ability of said affinity support to be used as a means for the purification of a coagulation protein, since
- said affinity support makes it possible to carry out purification processes for a coagulation protein having a very high degree of purity
- said affinity support does not detectably release undesirable substances, in particular nucleic aptamer molecules, into the eluate solution containing the purified coagulation protein,
- nucleic aptamer molecules does not entail disadvantages for human health
- said affinity support is inexpensive to manufacture, in particular because of the reduced costs of the production of the nucleic aptamers
- said affinity support for the purification of a coagulation protein is itself inexpensive because of the longevity of said support, due in particular to the possibility of regenerating it many times, and on a long period of time.
- the affinity support of the invention is capable of selectively reversibly fixing the target coagulation protein, with a good yield and a good specificity, in purification processes. from media of complex constitution, in particular from media conventionally used on an industrial scale, such as human plasma or culture media or biological fluids containing said protein of interest.
- the affinity support of the invention is capable of treating large volumes of solution containing the coagulation protein of interest. The affinity support of the invention is therefore a tool for purifying a coagulation protein that is perfectly well suited for use on an industrial scale.
- affinity support comprising immobilized nucleic aptamers for the purification of a coagulation protein under conditions of use on an industrial scale.
- affinity support comprising immobilized nucleic aptamers for the purification of a coagulation protein under conditions of use on an industrial scale.
- nucleic aptamers to thrombin, Factor VII and Factor IX (see PCT application WO 0 02/26932).
- selective binding is meant for the purposes of the present description the non-covalently specific binding of the coagulation protein of interest to the immobilized nucleic acids constituting the affinity support, and which is reversible by bringing the an affinity support on which non-covalent complexes have formed between said nucleic acids and said protein of interest with a suitable constitution solution, which may also be called an elution solution.
- the term "coagulation protein” is intended to mean any protein involved in the chain of reactions in cascade resulting in the formation of a blood clot.
- Coagulation proteins include Factor I (fibrinogen), Factor II (prothrombin), Factor V (proaccelerin), Factor VII (proconvertin), Factor VIII (antihemophilic factor A), Factor IX (factor Antihemophilic B), Factor X (Stuart Factor), Factor X1 (Rosenthal Factor or PTA), Factor XII (Hageman Factor), Factor XIII (Fibrin Stabilizing Factor or FSF), PK (Prekalicrin), KHPM (high molecular weight kininogen), tissue thromboplastin, heparin cofactor II (HCII), protein C (PC), thrombomodulin (TM), protein S (PS), Willlerbrand factor (Wf ) and the tissue factor pathway inhibitor (TFPI), or tissue factors.
- Factor I fibrinogen
- the coagulation protein is an enzymatically active coagulation protein.
- Enzymatic coagulation proteins include Factor II (prothrombin), Factor VII (proconvertin), Factor IX (antihemophilic factor B), Factor X (Stuart Factor), Factor X1 (Rosenthal Factor or PTA ), Factor XII (Hageman Factor), Factor XIII (Fibrin Stabilizing Factor or FSF) and PK (Prekalicrin).
- the coagulation protein consists of a natural or recombinant human coagulation protein.
- the coagulation protein is human, natural or recombinant factor VII.
- the solid supports on which the aptamers of the invention can be immobilized include any type of support having the structure and composition found commonly for filter supports, membranes, etc.
- Solid supports include, but are not limited to, resins, affinity chromatography resins, polymer beads, magnetic beads, paramagnetic beads, filter membrane support materials, and the like.
- Solid supports also include glass or metal-based materials such as steel, gold, silver, aluminum, copper, silicon, glass and ceramics.
- Solid supports also include, in particular, polymeric materials, such as polyethylene, polypropylene, polyamide, polyvinylidene fluoride, and combinations thereof.
- the solid support may be coated with a material facilitating attachment, attachment, complex formation, immobilization or interaction with aptamers, or with compounds comprising said aptamers.
- the solid support is a glass slide whose surface is coated with a gold layer, a carboxymethylation-treated layer, a layer of dextran, collagen, avidin, streptavidin, etc.
- the aptamers according to the invention or the compounds comprising the aptamers according to the invention, can be immobilized on the solid support by means of an attachment coating, as for example described above, either by chemical reaction with creation of covalent bonds, or by association by non-covalent bonds such as hydrogen bonds, electrostatic forces, Van der Waals forces, etc.
- an affinity support according to the invention in which the nucleic aptamers are immobilized, via the compounds in the structure of which they are included, by non-covalent bonds to the solid support material. .
- affinity supports comprising a solid support material on the surface of which streptavidin molecules are grafted, the nucleic aptamers being included in the structure of compounds comprising coupled aptamers at one of their ends. to a biotin molecule, and said aptamers being immobilized on said solid support material by non-covalent immobilization between the streptavidin molecules of the support material and the biotin molecules of the compounds comprising said nucleic aptamers.
- an affinity support comprising a support material on which streptavidin molecules are grafted.
- Such solid support materials are readily available commercially. "Nucleic acids specifically binding to a coagulation protein", or
- “Aptamers” or “nucleic aptamers” means molecules of DNA (deoxyribonucleic acid) or RNA (ribonucleic acid) having the capacity to bind to a coagulation protein of interest, greater than the capacity to bind to any other protein.
- the nucleic aptamers constituting the affinity support according to the invention have the ability to bind to a given human coagulation protein, greater than the ability to bind to any other human protein.
- the nucleic aptamers according to the invention notably have the capacity to bind to a given human coagulation protein, greater than the capacity to bind to any other homologous coagulation protein encoded by the genome of a non-human mammal.
- Human Factor VII has an ability to bind to human Factor VII greater than the ability to bind to Factor VII from a non-human mammal, including a rabbit Factor VII.
- a first nucleic acid has an ability to bind to human factor VIII / VIIa, which is greater than that of a second nucleic acid of equivalent mass, when, using any of the Binding above and under the same test conditions, a statistically significant upper binding signal value is obtained with the first nucleic acid, relative to that obtained with the second nucleic acid.
- the used link detection technique is the Biacore ® technique
- a first nucleic acid has a capacity to bind to VII / VIIa Factor, greater than that of a second nucleic acid equivalent weight, where resonance signal value for the first nucleic acid, regardless of the expressed resonance unit of measure, is statistically greater than the measured resonance signal value for the second nucleic acid.
- Two distinct "statistically" measured values encompass two values that are greater than the measurement error of the link detection technique used.
- a nucleic aptamer of an affinity support of the invention has a high affinity for the target coagulation protein.
- said nucleic aptamer has a Kd value, vis-a-vis said target coagulation protein, of less than 500 nM.
- the Kd value can be measured using the Biacore ® technique.
- nucleic aptamer comprising the sequence SEQ ID N 0 86 has a capacity to bind to VII / Factor VIIa that is significantly greater than its binding capacity at any factor VII / VIIa from a non-human mammal.
- a nucleic acid of sequence SEQ ID NO : 86 has a strong ability to bind to any type of human Factor VII / VIIa, including a natural Vll / VIIa Factor or a recombinant Vll / VIIa Factor, it has low or no ability to bind to a factor Vll / VIIa encoded by the genome of a non-human mammal, including a rabbit Vll / VIIa factor.
- the value of binding ability VII / VIIa factor, expressed as the dissociation constant Kd is about 100 nM.
- said nucleic aptamer has a binding capacity identical to both the human plasma Factor VII / VIIa and a recombinant human factor VII / VIIa, for example produced in a transgenic rabbit.
- the complex between a nucleic acid of sequence SEQ ID N 0 86 and a Factor Vll / VIIa are stoichiometric, ie the ratio of the number of nucleic acid molecules of SEQ ID No
- the number of complexed human Vll / VIIa molecules is about 1: 1 and can be in particular 1: 1.
- the affinity support of the invention can be used in a step of a method for purifying a recombinant human coagulation protein produced by a transgenic non-human mammal.
- the starting complex medium comprises the human recombinant protein in admixture with many proteins naturally produced by said transgenic mammal, including, as appropriate, the coagulation protein homologous to the recombinant human protein. It is understood that, in such embodiments, it is advantageous for the nucleic aptamers constituting the affinity support of the invention to bind selectively to the human protein of interest and not to bind under the same operating conditions.
- the ability of said aptamers to bind "specifically" to the human coagulation protein of interest can also be expressed as the ratio of the dissociation Kd, respectively for the human protein and for the nonhuman mammalian homologous protein.
- the ability of said nucleic aptamer to bind specifically to the human protein of coagulation can also be expressed by the following condition (A):
- Non-human Kd is the dissociation constant of said nucleic aptamer for the non-human homologous protein, expressed in the same molar units.
- a nucleic aptamer specifically binding to said recombinant human protein can also be defined by a ratio Human Kd / nonhuman Kd less than 0.005.
- the nucleic aptamers constituting the affinity support of the invention may be prepared according to the technique called SELEX.
- the term "aptamer” as used encompasses a single-stranded nucleic acid molecule, DNA or RNA, capable of specifically binding to a protein.
- Aptamers generally comprise between 5 and 120 nucleotides and can be selected in vitro according to a process known as SELEX (Systematic Evolution of Ligands by Exponential Enrichment), which was initially described in particular in PCT application N 0 WO 1991/019813 ).
- SELEX Systematic Evolution of Ligands by Exponential Enrichment
- the SELEX aptamer selection process consists in bringing a protein into contact with a combinatorial library of nucleic acids, DNA or RNA (in general 1015 molecules), nucleic acids that do not bind to the target are removed, nucleic acids are isolated. binding to the target are isolated and amplified.
- a nucleic acid specifically binding to a coagulation protein of interest is preferentially included in a chemical structure, also referred to as a "compound” in the present description, also comprising spacer means and, if appropriate, a means of immobilization on a solid support.
- the nucleic aptamer is included in the structure of a compound of the following formula (I): [FIX] x - [SPAC] y - [APT] (I), wherein:
- FIX means an immobilization compound on a support
- - [APT] means a nucleic acid specifically binding to a coagulation protein, also referred to as a nucleic aptamer, - x is an integer equal to 0 or 1, and
- y is an integer equal to 0 or 1.
- [APT] is a sequence of deoxyribonucleic acid SEQ ID N 0 86.
- the "spacer chain" designated [SPAC] in the compound of formula (I) may be of any known type. Said spacer chain has the function of physically moving the nucleic acid away from the surface of the solid support on which said compound can be immobilized and to allow a relative mobility of the nucleic acid with respect to the surface of the solid support on which it can to be immobilized.
- the spacer chain limits or avoids that steric hindrances, due to an excessive proximity of the solid support and the nucleic acid, interfere with the binding events between said nucleic acid and coagulation protein molecules that can be put into operation. contact with it.
- the spacer chain is preferably bonded to the 5 'end or the 3' end of the aptamer nucleic acid.
- the spacer chain is bonded to both an end of the aptamer and the solid support.
- This spacer construction has the advantage of not directly immobilizing the aptamer on the solid support.
- the spacer chain is a nonspecific oligonucleotide or polyethylene glycol (PEG).
- PEG polyethylene glycol
- said spacer chain includes a polyethylene glycol PEG type (CI 8), sold for example by Sigma Aldrich.
- the nucleic acid can be chemically modified with different chemical groups such as groups that make it possible to immobilize said nucleic acid in a covalent manner, such as thiols, amines or any other group capable of react with chemical groups present on the solid support.
- the compound [FIX] consists of a compound chosen from
- the first type of compound [FIX] includes the bifunctional coupling agents, such as glutaraldehyde, SIAB or SMCC.
- SIAB described by Hermanson GT. (1996, Bioconjugate Techniques, San Diego: Press Academy, pp 239-242), is the compound of formula (I) below:
- the compound SIAB comprises two reactive groups, an iodoacetate group and a sulpho-NHS ester group respectively, these groups reacting respectively on amino and sulfhydryl groups.
- the SMCC compound which is described by Samoszuk M.K. et al. (1989, Antibody,
- the SMCC compound comprises two reactive groups, respectively an ester group
- Sulfo-NHS and a maleimide group which react respectively with an amino group and a sulfhydryl group.
- the second type of compound [FIX] includes biotin, which is capable of specifically non-covalently binding to avidin or streptavidin molecules present on the mobile support.
- the aptamer is advantageously modified at its free end (end not bound to the spacer) by means of, and not limited to, a chemically modified nucleotide (such as 2 ' omethyl or 2'fluoropyrimidine, 2 'ribopurine, phosphoramidite), an inverted nucleotide or a chemical group (PEG, polycations, cholesterol).
- a chemically modified nucleotide such as 2 ' omethyl or 2'fluoropyrimidine, 2 'ribopurine, phosphoramidite
- PEG polycations, cholesterol
- a nucleic acid specifically binding to a coagulation protein is selected from DNA and RNA.
- nucleic aptamers capable of binding to various proteins involved in the pathway of blood coagulation including aptamers binder Willebrand factor (PCT Application No. WO 2008/150495 0) of aptamers binding alpha-thrombin (euocheren patent application No. EP 0 1972693) or thrombin (Zhao et al, 2008, Anal Chem, Vol 80 (19):..
- aptamers binder factor IX / IXa (Subash et al, 2006, Thromb Haemost, Vol 95: 767-771; Howard et al, 2007, Atherioscl Thromb Vase Biol, Vol. 27:... 722-727; PCT Application No. WO 2002/096926 0 ; US Patent No. US 7312325 0), aptamers binding factor X / Xa (PCT Application No. WO 2002/096926 0; US Patent No. US 7,312,325).
- Nucleic aptamers binding to human factor VIII / VIIa have also been described in the state of the art (Rusconi et al., 2000, Thromb Haemost, Vol 84 (5): 841-848, Layzer et al., 2007 , Spring, Vol 17: 1 -1 1.
- the nucleic aptamers consist of DNA aptamers.
- said immobilized nucleic acids where appropriate included in the structure of a compound of formula (I), consist of deoxyribonucleic acids.
- nucleic acids consist, for a first part of them, of deoxyribonucleic acids, and for the remaining part of ribonucleic acids.
- nucleic aptamers Another advantage of nucleic aptamers relates to their ease of manufacture, compared to the difficulties of synthesis of RNA aptamers, as well as their cost price which is significantly lower than the cost price of an aptamer RNA. These specific embodiments are illustrated in the examples.
- the present invention also relates to an affinity chromatography device for the purification of a coagulation protein, comprising a container in which is disposed a suitable amount of an affinity support as defined in the present description.
- containers for chromatographic media are known in the state of the art and are encompassed by the meaning of the term "container" above. Important features of such a container include the presence of feed means of the starting sample affinity chromatography device and liquid outlet means after contacting with the affinity support.
- the present invention also relates to a method for immobilizing a coagulation protein on a support, comprising a step during which a sample containing said coagulation protein is brought into contact with an affinity support as defined herein. above.
- sample containing a coagulation protein is generally meant any type of liquid solution in which said coagulation protein is in suspension or is solubilized. Specific embodiments of such a sample, particularly in connection with the purification process described hereinafter, will be defined later in this specification.
- the present invention also relates to a method for purifying a coagulation protein comprising the following steps: a) contacting a sample containing a coagulation protein with an affinity support as defined in the present description , to form complexes between (i) the nucleic aptamers immobilized on said affinity support and (ii) said coagulation protein, and b) releasing the protein from the complexes formed in step a), and c ) recovering said coagulation protein in a purified form.
- said sample contains a human coagulation protein.
- the sample containing a coagulation protein of interest consists of a liquid sample which contains said protein of interest, including a liquid sample comprising said protein of interest and which is capable of containing also molecules of the homologous coagulation protein of a non-human mammal.
- said sample consists of a biological solution, such as body fluid, cell, cell groyne, tissue, tissue mill, organ, or whole organism.
- said sample consists of a liquid biological solution from an animal such as blood, a blood derivative (blood derivative), mammalian milk, or a milk derivative. mammal.
- Said sample may consist of plasma, plasma cryoprecipitate, clarified milk or their derivatives.
- said sample is derived from a transgenic animal for the protein of human interest.
- the solution is mammalian milk or a transgenic mammalian milk derivative for said protein of human interest.
- the transgenic animals include (i) non-human mammals such as cows, goats, rabbits, pigs, monkeys, rats or mice, (ii) birds or (iii) ) insects such as mosquitoes, flies or silkworms.
- the transgenic animal for the human protein of interest is a non-human transgenic mammal, most preferably a transgenic rabbit for said protein of human interest.
- the transgenic mammal produces said recombinant human protein of interest in its mammary glands, because of the insertion into its genome of an expression cassette comprising nucleic acid encoding said protein of interest which is placed under the control of a specific promoter allowing the expression of the transgene protein in the milk of said transgenic mammal.
- a method for producing said human coagulation protein in the milk of a transgenic animal may comprise the following steps: a DNA molecule comprising a gene encoding the protein of interest, said gene being under the control of a promoter of a naturally secreted protein in the milk (such as the casein, beta-casein, lactalbumin, beta-lactoglobulin promoter or the WAP promoter) is integrated into an embryo of a non-human mammal. The embryo is then placed in a female mammal of the same species. Once the mammal from the embryo has grown sufficiently, the lactation of the mammal is induced, then the milk collected. The milk then contains the recombinant human protein of interest.
- a promoter of a naturally secreted protein in the milk such as the casein, beta-casein, lactalbumin, beta-lactoglobulin promoter or the WAP promoter
- a plasmid containing the WAP (Whey Acidic Protein) promoter is manufactured by introducing a sequence comprising the promoter of the WAP gene, this plasmid being made in such a way as to be able to receive a foreign gene placed under the control of the WAP promoter.
- the plasmid containing the promoter and the gene coding for the protein of the invention are used to obtain transgenic rabbits by microinjection into the male pronucleus of rabbit embryos. The embryos are then transferred into the oviduct of hormonally prepared females. The presence of the transgenes is revealed by the Southern technique from the DNA extracted from the transgenic rabbits obtained. Concentrations in animal milk are evaluated using specific radioimmunoassays.
- the purification method of the invention is also perfectly adapted to obtaining a purified protein of coagulation from a sample of human blood plasma, or a fraction of human blood plasma, for example the cryoprecipitated fraction. of human blood plasma.
- the target coagulation protein is human.
- the sample comprises at least one non-human coagulation protein.
- said human coagulation protein is homologous to said non-human coagulation protein.
- said human coagulation protein is the homologue of said non-human coagulation protein
- the starting sample may consist of the raw material, either the human blood plasma sample, or a fraction thereof, or the body fluid of a mammal transgenic non-human for the protein of interest, and which contains said protein of interest to be purified.
- the body fluids of a transgenic non-human mammal include milk or a milk fraction, for example a delipidated milk fraction or a fraction depleted of casein micelles.
- the above embodiment is not the preferred embodiment of the purification process of the invention, in particular because of the risk of clogging of the affinity support by the numerous proteins present in the raw sample of the invention. departure.
- said starting sample consists of a liquid solution containing the coagulation protein of interest suspended in said solution, said liquid solution consisting of an intermediate product generated during a multipurification purification process. steps of a coagulation protein.
- the starting sample may consist of a chromatographic eluate. ion exchange performed from a milk filtrate of said non-human transgenic mammal. This particular embodiment of a purification process according to the invention is illustrated in the examples.
- the starting sample may consist of a filtrate of a deep filtration step performed on the cryoprecipitate fraction of a sample of human plasma.
- the conditions of use of the affinity support for carrying out the purification process of the invention are very similar to the conventional conditions of use of a conventional chromatographic support, for example of the immunocyte carrier type. affinity on which ligand antibodies are immobilized.
- the skilled person can for example refer to the Bailon et al. (Pascal Bailon, George K. Ehrlich, Wen-Jian Fung and Wolfgang Berthold, An Overview of Affinity Chromatography, Humana Press, 2000).
- step c) elution of the process of the invention are very advantageous for the purification of a coagulation protein.
- step a) an appropriate volume of the sample to be purified is contacted with the affinity support. Complexes are formed between (i) the nucleic aptamers immobilized on said affinity support and (ii) the coagulation protein of interest contained in the sample to be purified.
- buffer reduced concentration MgCl 2 is meant according to the invention a buffer whose final concentration of MgCl 2 is less than 1 mM.
- a buffer whose concentration of MgCl 2 is less than 1 mM includes buffers whose concentration of MgCl 2 is less than 0.5 mM, 0.1 mM, 0.05 mM and 0.01 mM, advantageously equal to 0 mM.
- the method comprises a step a ') washing the affinity support with a wash buffer.
- the process comprises a step a ') washing the affinity support by increasing the ionic strength, that is to say with a washing buffer whose ionic strength is increased relative to the ionic strength of step a) .
- the ionic strength of the washing buffer is increased by 2 to 500 times with respect to the ionic strength of step a).
- the ionic strength of the washing buffer is increased from 100 to 500 times, preferably from 200 to 500 times, relative to the ionic strength of step a).
- a washing buffer having a final NaCl concentration of at least 1M is preferably used.
- a wash buffer having a final NaCl concentration of at least 1 M includes wash buffers having a final NaCl concentration of at least 1.5 M, 2 M, 2.5 M or minus 3 M.
- a washing buffer used in step a ') of the process has a final NaCl concentration of at most 3.5 M.
- a washing buffer used in step a') of the process has a concentration of final NaCl content of between 1.5 and 3.5, preferably between 2 and 3.5, preferably between 2.5 and 3.5, preferably between 3 and 3.5.
- step a ') of a washing buffer having a high hydrophobicity, in particular a high concentration of propylene glycol makes it possible to effectively remove the non-ionically bound substances. specific to the affinity support without simultaneously sensibly affecting the binding of Factor VII to the affinity support.
- a wash buffer with a final propylene glycol content of at least 20% (v / v) is preferably used.
- a wash buffer having a final propylene glycol content of at least 20% includes wash buffers having a final propylene glycol content of at least 25% M, 30%, 35%, 40% , 45%, 50%, 55%, or at least 60% by volume, based on the total volume of the wash buffer.
- a wash buffer used in step a ') of the process has a final propylene glycol content of at most 50%.
- a washing buffer used in step a ') of the process has a final propylene glycol content of between 20% and 50%, preferably between 30% and 50%.
- the washing buffer used in step a ') contains both NaCl and propylene glycol as described above.
- Step b) consists of a step of eluting the molecules of the coagulation protein of interest having formed complexes with the nucleic aptamers during step a).
- a specific advantage of the purification process above is the possibility of carrying out the elution step by bringing into contact the complexes formed between (i) the immobilized nucleic aptamers on said affinity support and
- This technical advantage which is made possible by virtue of the characteristics of the affinity support of the invention, allows the elution of the coagulation protein without requiring any recourse to the use of drastic elution conditions, capable of denaturing, at least partially, the coagulation protein of interest.
- Said drastic conditions that are avoided include the use of an acid pH for the elution step, which is commonly practiced for protein purification methods on known affinity carriers, and most particularly on affinity carriers comprising immobilized antibodies.
- step b) is carried out by contacting the affinity support with an elution buffer containing a divalent ion chelating agent, preferably EDTA. .
- the elution buffer may contain a final concentration of EDTA of at least 1 mM and at most 30 mM.
- At least 1 mM includes at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 mM.
- “Not more than 30 mM” includes not more than 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12 or 11 mM.
- step c) the coagulation protein of interest is recovered and purified by collecting the eluate liquid obtained at the end of step b).
- a purified liquid composition of the coaglation protein of interest is obtained.
- Said purified liquid composition may then be suitably treated, according to any known method of packaging and preserving proteins, including by direct flotation or after dilution with a suitable solution, or by lyophilization, preferably under sterile and pyrogen-free conditions, and then storage under appropriate conditions, at ambient temperature, at -4 ° C. or at a low temperature, depending on the type of packaging chosen.
- the affinity support of the invention can, with the successive cycles of use for the purification of a coagulation protein of interest, undergo a reduction in its capacity. absorption, for example because the elution step c) does not systematically release all the protein molecules from coagulation, which reduces the number of free aptamer sites for subsequent cycles of purification.
- the purification method of the invention comprises an additional step d) of regenerating the affinity support, by contacting said affinity support with a regeneration solution.
- step d) of regeneration of the affinity support can be carried out by placing said support in contact with a 50 mM Tris buffer solution, 50% Ethylene Glycol, as illustrated in the examples.
- the above purification method makes it possible to obtain a coagulation protein with a very high degree of purity, possibly with a degree of purity greater than 99.95% by weight, by relative to the total weight of the proteins contained in the purified final product.
- the starting sample consists of a sample comprising the human protein of coagulation of interest in recombinant form in admixture with proteins naturally produced by the non-human transgenic mammal
- the final composition comprising the recombinant human protein of high purity is substantially free of proteins from said transgenic mammal, and in particular substantially free of proteins of said mammal homologous to said recombinant human protein .
- recombinant human factor VII produced in the milk of a transgenic rabbit comprises less than 1.5% by weight of the proteins. of said transgenic mammal, relative to the weight of said proteins initially contained in the starting sample.
- 85% by weight of the recombinant human factor VII present in the starting sample was contained in the final product with a high degree of purity in recombinant human factor VII, greater than 99, 95% of the weight of the proteins present.
- the present invention also relates to a purified composition of a recombinant human coagulation protein comprising at least 99.9% by weight of said recombinant human protein and which is substantially free of non-human proteins.
- the present invention also relates to a purified composition of a recombinant human coagulation protein comprising at least 99.9% by weight of said recombinant human protein and at most 0.1% by weight of non-human proteins. weight being expressed relative to the total protein weight of said purified composition.
- At least 99.9% includes at least 99.91%, 99.92%, 99.93%, 99.94%, 99.95%, 99.96%, 99.9%, 99.9%, 99.9%, 99.9%, 99.9%. , 97%, 99.98% and 99.99%.
- the present invention also relates to a purified composition as defined above, usable as a medicament.
- the invention also relates to a pharmaceutical composition comprising a purified composition of a recombinant human coagulation protein as defined above, in combination with one or more pharmaceutically acceptable excipients.
- the invention also relates to a purified composition as defined above for the treatment of coagulation disorders.
- the invention also relates to the use of a purified composition as defined above for the manufacture of a medicament for the treatment of coagulation disorders.
- aptamers specifically binding to a coagulation protein which may be advantageously used according to the invention, are described below.
- the Applicant has constructed a family of nucleic aptamers that bind specifically to coagulation proteins, and in particular to the human factor VII / VIIa, the existence of relationships between (i) the common structural features and (ii) the or the common functional characteristics.
- the family of nucleic acids, or nucleic aptamers, specifically binding to the human factor VII / VIIa and usable according to the invention comprises at least 15 consecutive nucleotides of a polynucleotide having at least 40% d nucleotide identity with the nucleic acid of formula (I) below:
- SEQ ID N 0 X is a nucleic acid selected from the group consisting of nucleic acid sequences SEQ ID No. 3 to SEQ ID No. 85 and SEQ ID NO: 87 to SEQ ID
- - "x" is an integer equal to 0 or 1
- - "y" is an integer equal to 0 or 1.
- the acid of sequence SEQ ID N 0 X has a length of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides.
- the nucleic acid of sequence SEQ ID N 0 X has a length of 43, 44, 45, 46, 47, 48 or 49 nucleotides in length.
- the nucleic acid of sequence SEQ ID N 0 X has a length of 43, 44 or 45 nucleotides in length.
- the nucleic acid of formula (I) is at least 15 nucleotides in length. In some embodiments, the nucleic acid of formula (I) has at least 15, 16,
- nucleotides in length which includes nucleic acids having exactly each of the specified lengths.
- the successive cycles of selection carried out to construct the family of nucleic acids of interest that bind specifically to coagulation proteins have resulted in isolating and characterizing , at each successive step of selection, sets and subsets of nucleic aptamers comprising, at their ends, 5 'and 3', respectively the sequences SEQ ID No. 1 and SEQ ID No. 2, structurally framing a variable sequence SEQ ID N 0 X.
- the set of variable sequences SEQ ID N 0 X have between them a nucleotide sequence identity of at least 40%.
- the nucleic aptamers of the invention include nucleic acids comprising at least 15 consecutive nucleotides of a polynucleotide having at least 40% nucleotide identity with the nucleic acid of the following formula (1-1)
- the nucleic aptamers of the invention include nucleic acids comprising at least 15 consecutive nucleotides of a polynucleotide having at least 40% nucleotide identity with the nucleic acid of the following formula (I-2)
- nucleic aptamers of the invention include nucleic acids comprising at least 15 consecutive nucleotides of a polynucleotide having at least 40% nucleotide identity with the nucleic acid of the following formula (I-3):
- nucleic aptamers thus include nucleic acids comprising at least 15 consecutive nucleotides of a polynucleotide having at least 40% nucleotide identity with a nucleic acid selected from the group consisting of nucleic acids of SEQ ID NO: 3 sequences. to SEQ ID NO: 85 and SEQ ID NO: 87 to SEQ ID NO: 100.
- a first polynucleotide having at least 40% nucleotide identity with a second polynucleotide or nucleic acid has at least 41%, 42%, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59% , 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76 %, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 100% nucleotide identity with said second polynucleotide or nucleic acid.
- nucleic acid of the invention comprising the sequence SEQ ID N 0 X
- said sequence SEQ ID N 0 X is selected from the group consisting of nucleic acids having at least 15 consecutive nucleotides of a sequence possessing at least 40% nucleotide identity with at least one of SEQ ID NO : 3 to SEQ ID NO: 85 and SEQ ID NO: 87 to SEQ ID NO: 10 .
- nucleic acid of the invention comprising the sequence SEQ ID N 0 X
- said sequence SEQ ID N 0 X is chosen from the group consisting of nucleic acids having at least 41%, 42%, 43% , 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60% %, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% , 94%, 95%, 96%, 97%, 98% or 100% nucleotide identity with at least one of SEQ ID NO : 3 to SEQ ID NO: 85 and SEQ
- the present invention encompasses a family of single-stranded nucleic acids having at least 15 consecutive nucleotides of the sequence of formula (I) defined above.
- the "percent identity" between two nucleic acid sequences in the sense of the present invention is determined by comparing the two optimally aligned sequences through a comparison window.
- the part of the nucleotide sequence in the comparison window may thus comprise additions or deletions (for example "gaps") with respect to the reference sequence (which does not include these additions or deletions) so as to obtain a optimal alignment between the two sequences.
- the percent identity is calculated by determining the number of positions at which an identical nucleotide base is observed for the two compared sequences, and then dividing the number of positions at which there is identity between the two nucleobases by the total number of positions in the sequence. the comparison window, then multiplying the result by one hundred in order to obtain the percentage of nucleotide identity of the two sequences between them.
- the optimal alignment of the sequences for the comparison can be performed in a computer manner using known algorithms.
- the affinity support was made of a solid carrier material consisting of a matrix having grafted streptavidin (streptavidin-agarose - Novagen ®).
- a volume of 1 ml of gel was placed in a container consisting of a column (i.d., 1 mm). The gel was washed with purified water to remove the storage solvent
- the biotinylated anti-human FVII nucleic aptamers of sequence SEQ ID NO : 86 are solubilized in purified water at the final concentration of 0.5 mg / 0.187 ml, ie a final molar concentration of 0.1 mM.
- the nucleic aptamer solution was activated at 95 ° C. according to the standard cycle, for the immobilization of the aptamers on the solid support material.
- the nucleic aptamer solution was previously diluted with 4.8 ml of purified water and then 1.5 ml of Me ++ buffer (5x concentrate).
- the absorbance detector is adjusted to 1 AUFS (Absorbance Unit FuII Scale) and the OD is recorded at 254 nm of this solution at 0.575 AU 254 .
- the solution of biotinylated nucleic aptamers is injected onto the prepackaged streptavidin-agarose gel ("prepackaged") and recirculated with a peristaltic pump at a flow rate of 2.5 ml / minute, ie a contact time on the gel 24 seconds (input / output I / O). Under these conditions, the OD at 254 nm stabilizes rapidly at 0.05 AU 254 , a value of 91% theoretical coupling, that is to say 0.455 mg of nucleic aptamers per milliliter of gel.
- the aptamer affinity carriers were tested from a purified FVII / FVIIa preparation prepared according to the technique described in PCT Application No. WO2008 / 099077.
- the starting biological material is transgenic rabbit milk containing recombinant human FVII.
- the expression cassette comprises the human FVII transgene placed under the control of the ⁇ -casein gene promoter. Briefly, 140 milliliters of milk were collected from 2 rabbits in first lactation between Day 4 and Day 12 after calving.
- the average amidolytic FVII titre (biologically activatable FVII) in the milk collected is 928 IU / ml.
- the milks are stored at a temperature of -80 ° C.
- the rabbit milks are thawed in a water bath at a temperature of 37 ° C. and are then diluted with a solution of sodium citrate for a final citrate concentration of 62 g / l at a pH of 7. 5.
- the lipid-rich protein solution of the milk is then clarified on a sequence of filters, respectively (i) filter depth of 15 to 0.5 ⁇ m porosity threshold and (i) 0.2 ⁇ m membrane filter.
- a volume of 360 ml of filtered solution with a FVII titre of 198 IU / ml, ie 36 mg of transgenic FVII, is pre-purified on a MEP-HyperCel® chromatography gel (PaII
- a quantity of 17.5 mg of low purity FVII (-5%) obtained at the end of the above step is purified by ion exchange chromatography, using a Q-sepharose® XL gel ( GE Healthcare) with a volume of 20 ml.
- the human FVII is eluted with a volume of 78 ml of buffer comprising 5 mM calcium chloride.
- the residual proteins from rabbit milk are difficult to separate from FVII at this stage, either because there are homologies of structures such as GLA domain or EGF domain proteins, or physico-chemical homologies (ionic charge and / or near molecular size).
- Conventional techniques allow up to 99.95% purity improvement by orthogonal techniques (combination of hydroxyapatite gel separation and size exclusion chromatography).
- orthogonal techniques combination of hydroxyapatite gel separation and size exclusion chromatography
- the exogenous protein loading allowed for the genetic recombination proteins must not exceed 50 ppm, ie purity> 99.995%. Such purity only seems attainable after purification on an affinity matrix.
- a volume of 6 ml of the purified human FVII solution (1.1 mg FVII) obtained at the end of the previous step is used for the high purity purification step of recombinant human FVII with the support. affinity of the invention.
- the FVII solution obtained in the preceding step previously adjusted to 4 mM MgCl 2 and 10 mM CaCl 2 and pH 7.5, is injected onto the Aptamer-agarose gel (affinity support) with a peristaltic pump at a flow rate of 0.1 ml / minute is a contact time with the 10-minute affinity support (I / O).
- the gel is washed in 50mM tris buffer + 5mM NaCl + 4mM MgCl 2 + 10mM CaCl 2 at pH 7.5.
- a volume of 10 ml of non-adsorbed solution is collected.
- FVII is eluted with 50mM tris buffer + 10mM EDTA pH 7.5.
- the collection of the elution peak is carried out according to the DO profile.
- the amount of immobilized nucleic aptamers in the affinity support is 17 nanomoles, which corresponds, for a mole to mole interaction with the FVII molecules, to an absolute capacity of the affinity support of 0. , 9 mg of FVII.
- Figure 1 illustrates a chromatographic profile of recombinant human FVII produced in rabbit milk, with continuous monitoring of absorbance (OD) values at 254 nanometers.
- the inflection (2) of the absorption curve after the moment of the injection (1) illustrates the beginning of the saturation of the affinity support with the recombinant human FVII.
- time (3) the injection of recombinant human FVII is stopped.
- the duration between the injection start time (1) and the injection end time (2) is 10 minutes.
- the affinity support continues to saturate with the coagulation protein of interest: complexes between (i) the anti-FVII nucleic aptamers of the affinity support and (ii) the recombinant human FVII molecules initially contained in the composition to be purified have been formed.
- a washing step (6) of the column is carried out with the wash buffer specified above.
- the elution step is carried out by injection at the time (4) of the buffer solution comprising a final concentration of 10 mM EDTA.
- the absorption peak illustrates the release of recombinant human FVII from recombinant nucleic Aptamer / FVII complexes. It is noted that the recombinant human FVII molecules are released rapidly and therefore in a small volume. Therefore, thanks to the affinity support of the invention, a high concentration elution solution of recombinant human FVII protein is obtained.
- a step of regeneration of the affinity support was carried out with a 50 mM Tris buffer.
- the visible absorbance peak in (7) corresponds to the substances released from the affinity support because of the regeneration step.
- Table 1 presents the results of the test, which show a dynamic adsorption capacity of 0.45 to 0.49 mg / ml of the affinity matrices, ie 50 to 55% of bio-available ligands.
- Dynamic elution yield (for "Dynamic Elution”); which represents the ratio between the recombinant FVII eluted and the recombinant FVII adsorbed, expressed as a percentage Specific separation capacity of the affinity support
- the affinity supports were evaluated for specificity by a specific ELISA assay for rabbit milk proteins.
- Example 2 illustrate the excellent characteristics of the Aptamer-Agarose (Apta-2) gel affinity carriers with a dynamic adsorption capacity of at least 1 mg of FVII per mg of ligand with a yield of elution of at least 75%. Specificity is also well established with a clear improvement in purity (-99.95%), elimination of 2 log TM of residual rabbit milk protein RMPs. The final rate is about 500 ppm on these 2 non-optimized trials.
- the aptamer used is the aptamer of sequence SEQ ID N 0 101
- the starting material consists of a composition enriched in Factor IX derived from human plasma, which is marketed by LFB under the name Betafact®.
- Raw material injected Betafact MPVP (plasma FIX at 60% purity), load of 200 IU (ie 800 ⁇ g) of factor IX per ml of gel, contact time 10 minutes.
- Protein peaks are detected by measuring the absorbance value at the wavelength of 280 nanometers.
- Figure 2 shows the curve of measured values of absorbance at 280 nm versus time.
- peak # 1 is the fraction of the starting material that was not retained on the column.
- Peak No. 2 corresponds to the elution fraction.
- Peak No. 3 corresponds to the desorbed fraction of the support by the implementation of the regeneration step.
- FIG. 3 is a schematic of an SDS PAGE electrophoresis gel. From the left to the right of the gel in Figure 3 the tracks represent the migration results of the following starting materials:
- Table 3 summarizes the percentages of purity of FIX obtained by integration of the electrophoretic profile in the different fractions.
- The% of FIX is calculated according to a procedure well known to those skilled in the art, by quantitative integration of the densities of the electrophoretic bands of the gel stained with CBB (numerical data corresponding to FIG. 3).
- the quantitative integration of the densities of the electrophoretic bands can be obtained by scanning the gel with a suitable scanner.
- Example 4 Purification method of the recombinant factor IX contained in a transgenic sow milk extract A. Materials and Methods
- the aptamer is directly attached to the chromatographic support material by a chemical coupling reaction.
- the aptamer used is the aptamer Mapt 1 SEQ ID N 0 101 sequence A.2.
- the starting product is the aptamer Mapt 1 SEQ ID N 0 101 sequence A.2.
- the starting material consists of a clarified and pre-purified transgenic sow milk on MEP
- HyperCel 1, 8% purity Sample dialysed against the adsorption buffer / equilibration of the resin to remove sodium citrate. Charge of 302 IU (ie 1200 ⁇ g) of factor IX per ml.
- Regeneration 0.020 M Tris-HCl, 1 M NaCl, 50% Propylene Glycol, pH 7.5.
- the sample is injected at a flow rate of 0.1 ml / min for 10 min, the gel is then washed for 5 min at 0.5 ml / min. Elution and regeneration are carried out by injection of 2 ml of each of the buffers with a flow rate of 0.5 ml / min.
- Protein peaks are detected by measuring the absorbance value at the wavelength of
- NOVEX gels (Invitrogen) 10 wells, 4-12%, Bis-Tris; MES migration buffer, migration to
- Serachrom 0943 (Stago) according to the supplier's recommendations.
- Figure 4 shows the curve of measured values of absorbance at 280 nm versus time.
- peak # 1 is the fraction of the starting material that was not retained on the column.
- Peak No. 2 corresponds to the elution fraction.
- Peak No. 3 corresponds to the desorbed fraction of the support by the implementation of the regeneration step.
- the results of FIG. 4 show that the elution peak is very narrow, which illustrates the very high specificity for the human factor IX of the chromatographic support on which the aptamer is immobilized.
- Figure 5 is a schematic of an SDS PAGE electrophoresis gel. From the left to the right of the gel in Figure 5 the tracks represent the migration results of the following starting materials:
- results of the example illustrate the important degree of enrichment in human factor IX which is obtained after passing the starting material of complex composition on the affinity chromatography support on which the Mapt 2 aptamer is immobilized.
- the eluate has a good electrophoretic purity with a high purity gain relative to the starting material (> 26 times).
- the second band identified in the eluate certainly corresponds to another form of FIX.
- the aptamer used is the aptamer Mapt-2 Core sequence SEQ ID N 0 20 A.2.
- the starting product is the aptamer Mapt-2 Core sequence SEQ ID N 0 20 A.2.
- the starting material consists of a 98% purified human plasma factor VII composition.
- Protein peaks are detected by measuring the absorbance value at the wavelength of 280 nanometers.
- Figure 6 shows the curve of measured values of absorbance at 280 nm versus time.
- peak # 1 is the fraction of the starting material that was not retained on the column.
- Peak No. 2 corresponds to the elution fraction.
- lane no. 1 corresponds to the fraction of the starting material and lane no. 2 to the elution fraction. Despite the high purity of the starting material, it is found that the eluted fraction no longer contains contaminant or degraded forms
- Example 6 Absence of Aptamer Binding to Rabbit FVII A.
- Materials and Methods A.1. The support of affinity chromatoqraphy Affinity gel coupled to streptavidin on which the sequence SEQ ID N aptamer was immobilized 0 86 via a spacer chain (Novagen Provider) via a biotin at the 5 'terminal with a theoretical ligand density 0 , 35 mg / ml: volume 1 ml,
- the aptamer used is the sequence SEQ ID N aptamer 0 86
- Protein peaks are detected by measuring the absorbance value at the wavelength of
- a solid support was made on which were immobilized molecules of the nucleic aptamer of the invention of sequence SEQ ID NO : 86, also referred to herein as "Mapt2".
- Mapt2 Prior to its attachment to the solid support, the 5 'end of the aptamer Mapt2 was chemically coupled to a spacer chain consisting of 4 molecules of PEG (IC 8). Then, the free end of the spacer chain, opposite to the aptamer coupled end, was coupled to a biotin molecule.
- a solid support containing immobilized streptavidin molecules (S sensor Chip SA series, GE) was then added.
- the above solid support was then contacted with the aptamer compounds above to immobilize the nucleic acids of the present invention.
- sequence SEQ ID NO : 86 by non-covalent association between the streptavidin molecules of the support and the biotin molecules of the aptamer compounds.
- the aptamer Mapt2 is thus immobilized with a immobilization rate of 3772 RU (1 RU corresponds to approximately 1 ⁇ g of immobilized product per mm 2 ).
- Transgenic human FVII resulting purified from transgenic rabbit milk was diluted in running buffer (Tris 50 mM, NaCl 50 mM, CaCl 2 10 mM, MgCl 2 4 mM, pH 7.4) so as to obtain a sample of concentration 20 mM FVII.
- the sample was injected onto the chip (solid support) containing the aptaptin Mapt2 immobilized by a biotin-streptavidin interaction.
- buffers of increasing concentration of NaCl were injected onto the solid support (3 injection series ranging from 1 M NaCl to 3 M NaCl). All injections were performed with a flow rate of 30 ⁇ l / min for 60 sec after the injection.
- elution buffer (EDTA, 1 OmM) was then injected for 75 sec with a flow rate of 30 ⁇ l / min to unhook the FVII HPTG from the aptamer.
- EXAMPLE 8 Specific Embodiments of an Interaction Protocol for Human Factor VII with an aptamer on Biacore (propylene resistance qvolcol)
- a solid support was made on which were immobilized molecules of the nucleic aptamer of the invention of sequence SEQ ID NO : 86, also referred to herein as "Mapt2".
- Mapt2 Prior to its attachment to the solid support, the 5 'end of the aptamer Mapt2 was chemically coupled to a spacer chain consisting of 4 molecules of PEG (IC 8). Then, the free end of the spacer chain, opposite to the aptamer coupled end, was coupled to a biotin molecule.
- a solid support containing immobilized streptavidin molecules is available (S sensor chip SA series, GE)
- the solid support was contacted with the above aptamer compounds above in order to immobilize the nucleic acids of sequence SEQ ID N 0 86, by noncovalent association between the streptavidin molecules of the substrate and molecules of biotin aptamer compounds.
- the aptamer Mapt2 is thus immobilized with a immobilization rate of 5319 RU (1 RU corresponds to approximately 1 ⁇ g of immobilized product per mm 2 ).
- Transgenic human FVII resulting purified from transgenic rabbit milk was diluted in running buffer (Tris 50 mM, CaCl 2 10 mM, MgCl 2 4 mM, pH 7.4) in order to obtain a sample of concentration 20 mM FVII.
- the sample was injected onto the chip (solid support) containing the aptaptin Mapt2 immobilized by a biotin-streptavidin interaction.
- a buffer containing 50% propylene glycol was injected onto the solid support. All injections were performed with a flow rate of 30 ⁇ l / min for 60 sec after the injection.
- elution buffer EDTA, 1 OmM
- Mapt2 aptamer binding results to human FVII determined that binding of Mapt2 aptamer to human FVII was not impaired by injection of the propylene glycol-containing buffer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10710076A EP2398904A1 (fr) | 2009-02-19 | 2010-02-19 | Moyens pour la purification d'une protéine de la coagulation, et procèdes pour sa mise en oeuvre |
AU2010215303A AU2010215303B2 (en) | 2009-02-19 | 2010-02-19 | Means for purifying a coagulation protein, and methods for implementing same |
CA2753170A CA2753170A1 (fr) | 2009-02-19 | 2010-02-19 | Moyens pour la purification d'une proteine de la coagulation, et procedes pour sa mise en oeuvre |
BRPI1008043A BRPI1008043A2 (pt) | 2009-02-19 | 2010-02-19 | suporte de afinidade para fixação seletiva de uma proteína da coagulação, processos para imobilizar uma proteína da coagulação sobre um suporte e para purificar uma proteína da coagulação humana recombinante, e composição farmacêutica |
US13/201,722 US20120040905A1 (en) | 2009-02-19 | 2010-02-19 | Means for purifying a coagulation protein, and methods for implementing same |
CN2010800170464A CN102405288A (zh) | 2009-02-19 | 2010-02-19 | 纯化凝固蛋白的手段和实施其的方法 |
JP2011550636A JP2012517826A (ja) | 2009-02-19 | 2010-02-19 | 凝固タンパクの精製手段と、その実施方法 |
IL214566A IL214566A0 (en) | 2009-02-19 | 2011-08-09 | Means for purifying a coagulation protein, and methods for implementing same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0951081 | 2009-02-19 | ||
FR0951081A FR2942232B1 (fr) | 2009-02-19 | 2009-02-19 | Moyens pour la purification d'une proteine de la coagulation et procedes pour sa mise en oeuvre |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010094900A1 true WO2010094900A1 (fr) | 2010-08-26 |
Family
ID=42115926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2010/050293 WO2010094900A1 (fr) | 2009-02-19 | 2010-02-19 | Moyens pour la purification d'une protéine de la coagulation, et procèdes pour sa mise en oeuvre |
Country Status (11)
Country | Link |
---|---|
US (1) | US20120040905A1 (fr) |
EP (1) | EP2398904A1 (fr) |
JP (1) | JP2012517826A (fr) |
KR (1) | KR20110127661A (fr) |
CN (1) | CN102405288A (fr) |
AU (1) | AU2010215303B2 (fr) |
BR (1) | BRPI1008043A2 (fr) |
CA (1) | CA2753170A1 (fr) |
FR (1) | FR2942232B1 (fr) |
IL (1) | IL214566A0 (fr) |
WO (1) | WO2010094900A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011012831A1 (fr) * | 2009-07-31 | 2011-02-03 | Lfb Biotechnologies | Procede pour la purification de proteines de la coagulation a domaine gla actives |
WO2011012830A1 (fr) * | 2009-07-31 | 2011-02-03 | Lfb Biotechnologies | Procede pour la purification de proteines de la coagulation a domaine gla |
JP2014507147A (ja) * | 2011-02-11 | 2014-03-27 | バクスター・インターナショナル・インコーポレイテッド | 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用 |
WO2018007530A1 (fr) * | 2016-07-06 | 2018-01-11 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Aptamères anti-fibrinogène et utilisations associées |
CN114438061A (zh) * | 2020-10-30 | 2022-05-06 | 北京双鹭立生医药科技有限公司 | 用于纯化凝血因子vii的方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112107557A (zh) | 2013-03-14 | 2020-12-22 | Ran生物技术公司 | 用于检测生物物质的方法和材料 |
KR20150141950A (ko) | 2013-03-14 | 2015-12-21 | 랜 바이오테크놀러지스, 인크. | 미생물유기체 포획을 위한 방법 및 물질 |
CN107614565B (zh) | 2015-04-21 | 2021-04-09 | Ran生物技术公司 | 氟化表面活性剂 |
EP3756010A4 (fr) | 2018-02-20 | 2021-11-03 | Pavonis Diagnostics Inc. | Surfaces d'oxyde d'aluminium et molécules d'interface |
CN110423755A (zh) * | 2019-06-30 | 2019-11-08 | 中国人民解放军第四军医大学 | 一种纤维蛋白核酸适配子及其应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991019813A1 (fr) | 1990-06-11 | 1991-12-26 | The University Of Colorado Foundation, Inc. | Ligands d'acide nucleique |
EP0527063A1 (fr) | 1991-06-12 | 1993-02-10 | Institut National De La Recherche Agronomique | Production d'une protéine d'intérêt dans le lait d'un mammifère transgènique |
EP0668931A1 (fr) | 1992-09-29 | 1995-08-30 | NeXstar Pharmaceuticals, Inc. | Ligands d'acide nucleique et procedes de production |
WO2002026932A2 (fr) | 2000-09-26 | 2002-04-04 | Duke University | Aptameres d'arn et procede d'identification desdits aptameres |
WO2002096926A1 (fr) | 2001-05-25 | 2002-12-05 | Duke University | Modulateurs d'agents pharmacologiques |
US7045676B1 (en) | 1986-04-09 | 2006-05-16 | Gtc Biotherapeutics, Inc. | Transgenic animals secreting proteins into milk |
EP1739170A2 (fr) | 1994-09-21 | 2007-01-03 | American National Red Cross | Animaux transgéniques exprimant le facteur VIII de coagulation chez l'homme et le facteur von Willebrand |
WO2007035532A2 (fr) * | 2005-09-15 | 2007-03-29 | Duke University | Banques ciblees, profilage fonctionnel, laser selex et deselex |
WO2008099077A2 (fr) | 2006-12-29 | 2008-08-21 | Lfb Biotechnologies | Procédé d'extraction d'une protéine présente dans du lait |
EP1972693A1 (fr) | 2007-03-14 | 2008-09-24 | Korea Institute of Science and Technology | Procédé et kit pour la détection d'une protéine cible utilisant un aptamère d'ADN |
WO2008150495A2 (fr) | 2007-06-01 | 2008-12-11 | Archemix Corp. | Formulations d'aptamère vwf et procédés d'utilisation |
WO2009024726A2 (fr) * | 2007-08-14 | 2009-02-26 | Lfb - Biotechnologies | Procede de purification ou de detection d'une proteine cible |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1918372A4 (fr) * | 2005-07-05 | 2009-08-12 | Ribomic Inc | Acide nucléique capable de se lier à une immunoglobuline g et son utilisation |
RU2008139428A (ru) * | 2006-03-06 | 2010-05-20 | Хьюмэджин, Инк. (Us) | Способ получения рекомбинантного тромбина и фибриногена человека |
CN1912138A (zh) * | 2006-03-31 | 2007-02-14 | 华东师范大学 | 识别蛋白质序列的寡聚核苷酸适配子在蛋白质组学研究中的应用 |
JP2008175750A (ja) * | 2007-01-20 | 2008-07-31 | Iwai Chemicals Co Ltd | 被検物質の検出方法 |
WO2008108004A1 (fr) * | 2007-03-05 | 2008-09-12 | On-Chip Cellomics Consortium | Puce d'échantillonnage d'un composant de cellule, système d'analyse d'un composant de cellule et procédé d'analyse d'un composant de cellule au moyen de celui-ci |
-
2009
- 2009-02-19 FR FR0951081A patent/FR2942232B1/fr not_active Expired - Fee Related
-
2010
- 2010-02-19 WO PCT/FR2010/050293 patent/WO2010094900A1/fr active Application Filing
- 2010-02-19 CA CA2753170A patent/CA2753170A1/fr not_active Abandoned
- 2010-02-19 AU AU2010215303A patent/AU2010215303B2/en not_active Ceased
- 2010-02-19 BR BRPI1008043A patent/BRPI1008043A2/pt not_active IP Right Cessation
- 2010-02-19 EP EP10710076A patent/EP2398904A1/fr not_active Withdrawn
- 2010-02-19 KR KR1020117019382A patent/KR20110127661A/ko not_active Application Discontinuation
- 2010-02-19 CN CN2010800170464A patent/CN102405288A/zh active Pending
- 2010-02-19 US US13/201,722 patent/US20120040905A1/en not_active Abandoned
- 2010-02-19 JP JP2011550636A patent/JP2012517826A/ja active Pending
-
2011
- 2011-08-09 IL IL214566A patent/IL214566A0/en unknown
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7045676B1 (en) | 1986-04-09 | 2006-05-16 | Gtc Biotherapeutics, Inc. | Transgenic animals secreting proteins into milk |
EP1695978A1 (fr) | 1990-06-11 | 2006-08-30 | Gilead Sciences, Inc. | Ligands constitués par des acides nucléiques |
EP0786469A2 (fr) | 1990-06-11 | 1997-07-30 | NeXstar Pharmaceuticals, Inc. | Ligands d'acide nucléique |
WO1991019813A1 (fr) | 1990-06-11 | 1991-12-26 | The University Of Colorado Foundation, Inc. | Ligands d'acide nucleique |
EP1493825A2 (fr) | 1990-06-11 | 2005-01-05 | Gilead Sciences, Inc. | Procédé pour la production de ligands constitués par des acides nucléiques |
EP0527063A1 (fr) | 1991-06-12 | 1993-02-10 | Institut National De La Recherche Agronomique | Production d'une protéine d'intérêt dans le lait d'un mammifère transgènique |
EP0668931A1 (fr) | 1992-09-29 | 1995-08-30 | NeXstar Pharmaceuticals, Inc. | Ligands d'acide nucleique et procedes de production |
EP1739170A2 (fr) | 1994-09-21 | 2007-01-03 | American National Red Cross | Animaux transgéniques exprimant le facteur VIII de coagulation chez l'homme et le facteur von Willebrand |
WO2002026932A2 (fr) | 2000-09-26 | 2002-04-04 | Duke University | Aptameres d'arn et procede d'identification desdits aptameres |
US7312325B2 (en) | 2000-09-26 | 2007-12-25 | Duke University | RNA aptamers and methods for identifying the same |
WO2002096926A1 (fr) | 2001-05-25 | 2002-12-05 | Duke University | Modulateurs d'agents pharmacologiques |
WO2007035532A2 (fr) * | 2005-09-15 | 2007-03-29 | Duke University | Banques ciblees, profilage fonctionnel, laser selex et deselex |
WO2008099077A2 (fr) | 2006-12-29 | 2008-08-21 | Lfb Biotechnologies | Procédé d'extraction d'une protéine présente dans du lait |
EP1972693A1 (fr) | 2007-03-14 | 2008-09-24 | Korea Institute of Science and Technology | Procédé et kit pour la détection d'une protéine cible utilisant un aptamère d'ADN |
WO2008150495A2 (fr) | 2007-06-01 | 2008-12-11 | Archemix Corp. | Formulations d'aptamère vwf et procédés d'utilisation |
WO2009024726A2 (fr) * | 2007-08-14 | 2009-02-26 | Lfb - Biotechnologies | Procede de purification ou de detection d'une proteine cible |
Non-Patent Citations (15)
Title |
---|
BALAMURUGAN SUBRAMANIAN ET AL: "Designing highly specific biosensing surfaces using aptamer monolayers on gold.", LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS, vol. 22, no. 14, 4 July 2006 (2006-07-04), pages 6446 - 6453, XP002581280, ISSN: 0743-7463 * |
BRUMBT ET AL., ANAL CHEM, vol. 77, 2005, pages 1993 - 1998 |
ELLINGTON; SZOSTAK: "In vitro selection of RNA molecules that bind specific ligands", NATURE, no. 6287, 30 August 1990 (1990-08-30), pages 818 - 22 |
GOPINATH ET AL: "Anti-coagulant aptamers", THROMBOSIS RESEARCH, vol. 122, no. 6, 2008, pages 838 - 847, XP025466375, ISSN: 0049-3848 * |
GRONEWOLD T M A ET AL: "Monitoring complex formation in the blood-coagulation cascade using aptamer-coated SAW sensors", BIOSENSORS AND BIOELECTRONICS, vol. 20, no. 10, 15 April 2005 (2005-04-15), pages 2044 - 2052, XP004769140, ISSN: 0956-5663 * |
HERMANSON G.T.: "Bioconjugate techniques", 1996, ACADEMIC PRESS, pages: 239 - 242 |
HOWARD ET AL., ATHERIOSCL THROMB VASC BIOL, vol. 27, 2007, pages 722 - 727 |
LAYZER ET AL., SPRING, vol. 17, 2007, pages 1 - 11 |
MICHAUD ET AL., ANAL CHEM, vol. 76, 2003, pages 1015 - 1020 |
QIANG ZHAO ET AL: "Aptamer-Based Affinity Chromatography Assays for Thrombin", ANALYTICAL CHEMISTRY, vol. 80, no. 19, 1 October 2008 (2008-10-01), pages 7586 - 7593, XP002557962, ISSN: 0003-2700 * |
RUSCONI ET AL., THROMB HAEMOST, vol. 84, no. 5, 2000, pages 841 - 848 |
SAMOSZUK M.K. ET AL., ANTIBODY, IMMUNOCONJUGATES RADIOPHARM., vol. 2, no. 1, 1989, pages 37 - 46 |
SUBASH ET AL., THROMB HAEMOST, vol. 95, 2006, pages 767 - 771 |
TUERK; GOLD: "Systematic evolution of ligands by exponential enrichment : RNA ligands to bacteriophage T4 DNA polymerase", SCIENCE, vol. 249, no. 4968, 1990, pages 505 - 10 |
ZHAO ET AL., ANAL CHEM, vol. 80, no. 19, 2008, pages 7586 - 7593 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9850477B2 (en) | 2009-07-31 | 2017-12-26 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for purifying active GLA-domain coagulation proteins |
WO2011012830A1 (fr) * | 2009-07-31 | 2011-02-03 | Lfb Biotechnologies | Procede pour la purification de proteines de la coagulation a domaine gla |
CN102666857A (zh) * | 2009-07-31 | 2012-09-12 | Lfb生物技术公司 | 纯化活性gla结构域凝固蛋白的方法 |
AU2010277421B2 (en) * | 2009-07-31 | 2015-10-22 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for purifying active GLA-domain coagulation proteins |
US9212365B2 (en) | 2009-07-31 | 2015-12-15 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for purifying active GLA-domain coagulation proteins |
AU2010277420B2 (en) * | 2009-07-31 | 2016-01-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for purifying GLA-domain coagulation proteins |
US9359610B2 (en) | 2009-07-31 | 2016-06-07 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Method for purifying GLA-domain coagulation proteins |
CN102666857B (zh) * | 2009-07-31 | 2017-03-08 | 法国血液分割暨生化制品实验室 | 纯化活性gla结构域凝固蛋白的方法 |
WO2011012831A1 (fr) * | 2009-07-31 | 2011-02-03 | Lfb Biotechnologies | Procede pour la purification de proteines de la coagulation a domaine gla actives |
JP2014507147A (ja) * | 2011-02-11 | 2014-03-27 | バクスター・インターナショナル・インコーポレイテッド | 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用 |
WO2018007530A1 (fr) * | 2016-07-06 | 2018-01-11 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Aptamères anti-fibrinogène et utilisations associées |
CN114438061A (zh) * | 2020-10-30 | 2022-05-06 | 北京双鹭立生医药科技有限公司 | 用于纯化凝血因子vii的方法 |
CN114438061B (zh) * | 2020-10-30 | 2023-10-20 | 北京双鹭立生医药科技有限公司 | 用于纯化凝血因子vii的方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2398904A1 (fr) | 2011-12-28 |
US20120040905A1 (en) | 2012-02-16 |
FR2942232B1 (fr) | 2015-03-13 |
AU2010215303A1 (en) | 2011-09-08 |
AU2010215303B2 (en) | 2015-05-21 |
CA2753170A1 (fr) | 2010-08-26 |
IL214566A0 (en) | 2011-09-27 |
KR20110127661A (ko) | 2011-11-25 |
JP2012517826A (ja) | 2012-08-09 |
BRPI1008043A2 (pt) | 2016-05-03 |
CN102405288A (zh) | 2012-04-04 |
FR2942232A1 (fr) | 2010-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2398818B1 (fr) | Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre | |
WO2010094900A1 (fr) | Moyens pour la purification d'une protéine de la coagulation, et procèdes pour sa mise en oeuvre | |
EP2178901B1 (fr) | Procede de purification ou de detection d'une proteine cible | |
EP2658864A1 (fr) | Procede d'immobilisation de ligands nucleiques | |
CA2771850C (fr) | Procede pour la purification de proteines de la coagulation a domaine gla actives | |
EP2785841B1 (fr) | Aptamères anti-fh, procédé pour leur obtention et utilisations | |
EP2459718B1 (fr) | Procede pour la purification de proteines de la coagulation a domaine gla | |
EP2398816A1 (fr) | ACIDES NUCLEIQUES SE LIANT SPECIFIQUEMENT AU FACTEUR VII/VIIa HUMAIN, ET UTILISATIONS | |
AU2015215875A1 (en) | Means for purifying a coagulation protein, and methods for implementing same | |
WO2015044923A2 (fr) | Acides nucleiques se liant specifiquement au facteur ix/ixa humain, et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080017046.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10710076 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 214566 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13201722 Country of ref document: US Ref document number: 2010215303 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6244/DELNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011550636 Country of ref document: JP Ref document number: 2010710076 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117019382 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2753170 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2010215303 Country of ref document: AU Date of ref document: 20100219 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1008043 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1008043 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110819 |